Ability of Calcium Bis Acetyl Homotaurine, a Gaba Agonist, to Prevent Relapse in Weaned Alcoholics

Lhuintre, J. P.; Moore, N; Saligaut, Christian; Boismare, F; Daoust, M.; Chrétien, Pierre; Tran, Giang N.; Hillemand, B

doi:10.1016/s0140-6736(85)91615-0

Cited by 154 publications

(37 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acamprosate has been shown to prevent relapse in weaned alcoholics (Lhuintre et al 1985;Sass et al 1996;Whitworth et al 1996) and to suppress alcohol consumption after a drug-free period in rats Hölter et al 1997;Heyser et al 1998). In view of the fact that alcohol and opioids share common properties at the behavioral and neurochemical levels (see Terenius 1996;Herz 1997 for review), we postulated that acamprosate might also interfere with processes involved in opioid dependence.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress

et al. 1998

View full text Add to dashboard Cite

Acamprosate (calcium-acetyl homotaurinate) is a new compound used in the treatment of alcohol abuse. Because of the putative link between alcoholism and the endogenous opioid systems in both humans and laboratory animals, we tested in rats the effects of acamprosate on behavioral and neurochemical effects of opioid drugs related to their abuse potential. These included sensitization to the behavioral effects of morphine, morphine-induced dopamine (DA) release in the nucleus accumbens (NAS), intravenous (i.v.) heroin self-administration and relapse to heroin seeking in drug-free rats. In experiment 1, rats were injected daily with either morphine (10 mg/kg, s.c.) or saline for 14 days. Three days later in a test for the expression of sensitization, an injection of morphine (10 mg/kg) resulted in increased locomotor activity and enhanced DA release in the NAS in rats previously exposed to morphine. Acamprosate (two injections of 200 mg/kg, 12 h apart; i.p.) suppressed the expression of the sensitized responses, but did not alter the effects of morphine in drug-naive control rats. In experiment 2, it was found that acamprosate (two injections of 50-200 mg/ kg; i.p.) had no consistent effects on i.v. heroin self-administration (50 100 microg/kg per infusion) and, in experiment 3, that acamprosate (100-200 mg/ kg, i.p.) did not alter reinstatement of drug seeking induced by priming injections of heroin (0.25 mg/kg, s.c.) or a footshock stressor (15 min; 0.5 mA) after a 5- to 8-day period of extinction. Thus, although acamprosate attenuated the expression of sensitized locomotor activity and DA release in the NAS, it did not have any consistent effect on either the intake of heroin during the maintenance phase or the relapse to heroin seeking in a drug-free state. Thus, to the extent that the self-administration and the reinstatement procedures provide valid preclinical models for drug use and relapse in humans, our data suggest that acamprosate may not be effective in altering drug-taking behavior in heroin users.

show abstract

Section: Discussionmentioning

confidence: 94%

“…Acamprosate (calcium-acetyl homotaurinate) is a new compound used for the prevention of relapse in abstinent alcoholics (Lhuintre et al 1985;Sass et al 1996;Whitworth et al 1996). It has also been shown that acamprosate reduces alcohol intake in rodents (Boismare et al 1984;Le Magnen et al 1987).…”

Section: Introductionmentioning

confidence: 99%

Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress

et al. 1998

View full text Add to dashboard Cite

show abstract

“…In this fashion, nine naltrexone studies (Anton et al, 1999;Chick et al, 2000a;Hersh et al, 1998;Kranzler et al, 1998Kranzler et al, , 2000O'Malley et al, 1992;Oslin et al, 1997;Volpicelli et al, 1992Volpicelli et al, , 1997 and 13 acamprosate studies (Besson et al, 1998;Chick et al, 2000b;Geerlings et al, 1997;Lhuintre et al, 1985Lhuintre et al, , 1990Paille et al, 1995;Pelc et al, 1992Pelc et al, , 1997Poldrugo, 1997;Roussaux et al, 1996;Sass et al, 1996;Tempesta et al, 2000;Whitworth et al 1996) were identified. The number of acamprosate studies was reduced to 11 by methodological concerns: Lhuintre et al (1985) reported data only on completers, and Lhuintre et al (1990) used only ␥-glutamyl transferase (GGT) as an outcome measure. Two studies of nalmefene, an opioid antagonist that has been studied as a treatment for alcohol dependence (Mason et al, 1994(Mason et al, , 1999, were not included in the analysis of naltrexone effects.…”

Section: Study Samplementioning

confidence: 98%

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis

Kranzler

Kirk

2001

Alcoholism Clin & Exp Res

358

View full text Add to dashboard Cite

show abstract

“…Following three early trials (Lhuintre et al 1985(Lhuintre et al , 1990Gerra et al 1992), five quite recent projects have further evaluated the value of acamprosate (Table 3). Paille et al (1995) conducted a 1-year, 31-site trial with 538 alcohol dependent patients in France.…”

Section: Acamprosatementioning

confidence: 99%

Advances in development of medications for alcoholism treatment

Litten

Allen

1998

Psychopharmacology

View full text Add to dashboard Cite

Over the past decade, research on medications to treat alcohol problem has flourished. Naltrexone and acamprosate are tangible fruits of such endeavors and each has now earned approval in a large number of countries. Recent studies on naltrexone indicate that patient compliance is important if full benefits are to be achieved. Several laboratory studies with human subjects are beginning to elucidate the mechanisms underlying efficacy of naltrexone, as well as explaining variability of response among subpopulations of drinkers. In addition to these two agents, recent investigations have also demonstrated that the antidepressants desipramine, imipramine, and fluoxetine reduce mood-related symptoms and, to some extent, drinking itself in alcoholics who are depressed. Research to date suggests that opioid antagonists and selective serotonin reuptake inhibitors are more effective in reducing alcohol intake when used in combination. Clinical issues, methodology, and directions for future research are also reviewed in this article. In particular, issues addressed include alternative dosage regimens, necessary duration of treatment, employment of medications in combination, integration of pharmacologic agents with behavioral interventions, enhancement of patient compliance, and concurrent treatment of psychiatric comorbidity.

show abstract

Ability of Calcium Bis Acetyl Homotaurine, a Gaba Agonist, to Prevent Relapse in Weaned Alcoholics

Cited by 154 publications

References 5 publications

Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress

Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis

Advances in development of medications for alcoholism treatment

Contact Info

Product

Resources

About